---
figid: PMC4659440__tog-suppl.1-2015-013f5
figtitle: c-Met as a Target for Personalized Therapy
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC4659440
filename: tog-suppl.1-2015-013f5.jpg
figlink: /pmc/articles/PMC4659440/figure/f5-tog-suppl.1-2015-013/
number: F5
caption: 'Functional crosstalk of HGF-MET signaling pathway with EGFR and VEGFR signaling
  pathway.Notes: The anticancer treatment with EGFR antibodies (cetuximab, panitumumab)
  or EGFR TKIs (gefitinib, erlotinib) leads to MET amplification with subsequent activation
  of PI3K-AKT signaling. The resistance can be prevented by dual inhibition of EGFR
  and MET. Similarly, MET-HGF signaling pathway activation help evade VEGFR inhibition
  induced by bevacizumab, sunitinib or pazopanib and dual inhibition with VEGFR and
  MET inhibitor might overcome the resistance to anticancer treatment.'
papertitle: c-Met as a Target for Personalized Therapy.
reftext: Ingrid Garajov√°, et al. Transl Oncogenomics. 2015;7(Suppl 1):13-31.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9670447
figid_alias: PMC4659440__F5
figtype: Figure
redirect_from: /figures/PMC4659440__F5
ndex: 4dec8b3e-dec6-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4659440__tog-suppl.1-2015-013f5.html
  '@type': Dataset
  description: 'Functional crosstalk of HGF-MET signaling pathway with EGFR and VEGFR
    signaling pathway.Notes: The anticancer treatment with EGFR antibodies (cetuximab,
    panitumumab) or EGFR TKIs (gefitinib, erlotinib) leads to MET amplification with
    subsequent activation of PI3K-AKT signaling. The resistance can be prevented by
    dual inhibition of EGFR and MET. Similarly, MET-HGF signaling pathway activation
    help evade VEGFR inhibition induced by bevacizumab, sunitinib or pazopanib and
    dual inhibition with VEGFR and MET inhibitor might overcome the resistance to
    anticancer treatment.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - VGF
  - EGF
  - HGF
  - IL6
  - SOS1
  - EGFR
  - KDR
  - FLT1
  - FLT4
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MTOR
  - pazopanib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
